University of Missouri Study Links Rapamycin to Brain Health
New research shows a transplant drug may improve cerebral blood flow in certain adults carrying the APOE4 gene variant.
Updated on Oct. 30, 2026 in Alzheimer’s
Live Poll
Do you trust that medical research targeting specific genetic risks will lead to effective preventative treatments?
A University of Missouri study published in the Journal of Cerebral Blood Flow & Metabolism found that daily low-dose rapamycin increases cerebral blood flow in middle-aged adults carrying the APOE4 gene variant. The effect was particularly notable in women, who account for two-thirds of Alzheimer’s patients.
Why it matters
Reduced cerebral blood flow is closely associated with the development of cognitive decline, making this finding a potential pathway for future preventative treatments. Researchers are now exploring if this intervention could eventually delay or prevent the onset of Alzheimer's disease.
The study tracked adults aged 45 to 65 who took a low dose of rapamycin daily over a 4-week period. While blood flow improved in APOE4 gene carriers, the study noted that participants without the variant showed no significant change.
The players
University of Missouri
A public land-grant research university that serves as the state’s primary center for higher education and medical investigation.
Roy Blunt NextGen Precision Health
A research facility at the University of Missouri that focuses on collaborative efforts to advance precision medicine and health outcomes.
The details
The research conducted at the Roy Blunt NextGen Precision Health facility tested whether rapamycin, a drug typically used to prevent organ transplant rejection, could mitigate blood flow reductions linked to the APOE4 gene. Women with the variant showed the most significant improvements in brain blood flow among the participants.
Timeline
The daily low-dose rapamycin administration lasted for 4 weeks.
The study findings were published on October 30, 2026.
Health Landscape
This study aligns with the broader goals of the National Institute on Aging's Alzheimer's Disease Research Centers program by testing repurposed pharmaceuticals for neuroprotection. The findings contribute to the evolving effort to identify early interventions for high-risk populations.
This study is an early-stage clinical finding and does not change current medical treatment or daily health routines for the public. Patients should not attempt to access or self-administer rapamycin for cognitive health without guidance from a medical professional.
The takeaway
While the results are promising for those at genetic risk, the drug used in this study is currently prescribed for transplant care and carries specific risks. Further clinical trials are required before this approach can be considered as a standard therapy for preventing memory loss.
Further reading
For more on ongoing research into cognitive health, visit the Alzheimer’s section.
Source note: This article includes information reported by FOX 13 Tampa Bay.
Live Poll
Do you trust that medical research targeting specific genetic risks will lead to effective preventative treatments?
